Search research articles
Contact Us
Filters
Showing results (91-100 of 350) with videos related to
Page
of 35
Sort By:
Future Oncology (London, England)
|
February 25, 2021
An evaluation of <i>RAS</i> testing among metastatic colorectal cancer patients in the USA
Laura Sangaré, Kimberly Delli-Zotti, Ana Florea, et al.
The Oncologist
|
October 6, 2022
Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs
Zhonglin Hao, Saurabh Parasramka, Quan Chen, et al.
American Health & Drug Benefits
|
December 22, 2017
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
Rajeev Ayyagari, Maureen Neary, Shang Li, et al.
Journal of Oncology Practice
|
November 28, 2012
Barriers to the use of personalized medicine in breast cancer
Christine B Weldon, Julia R Trosman, William J Gradishar, et al.
Journal of Cancer Research and Clinical Oncology
|
August 12, 2020
Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning
Yu Li, Aydin Eresen, Junjie Shangguan, et al.
World Journal of Gastroenterology
|
October 4, 2017
Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis
Al B Benson, Michael S Broder, Beilei Cai, et al.
Journal of Comparative Effectiveness Research
|
November 19, 2013
What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer
Julia R Trosman, Christine B Weldon, Julian C Schink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 28, 2004
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials
M Extermann, M Bonetti, G W Sledge, et al.
Journal of Medical Economics
|
June 1, 2017
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR
Lynn Huynh, Todor Totev, Francis Vekeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
Weijing Sun, Mark Powell, Peter J O'Dwyer, et al.
Page
of 35
Search research articles
Search
Showing results (91-100 of 350) with videos related to
Sort By:
Page
of 35
Future Oncology (London, England)
|
February 25, 2021
An evaluation of <i>RAS</i> testing among metastatic colorectal cancer patients in the USA
Laura Sangaré, Kimberly Delli-Zotti, Ana Florea, et al.
The Oncologist
|
October 6, 2022
Neoadjuvant Versus Adjuvant Chemotherapy for Resectable Metastatic Colon Cancer in Non-academic and Academic Programs
Zhonglin Hao, Saurabh Parasramka, Quan Chen, et al.
American Health & Drug Benefits
|
December 22, 2017
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
Rajeev Ayyagari, Maureen Neary, Shang Li, et al.
Journal of Oncology Practice
|
November 28, 2012
Barriers to the use of personalized medicine in breast cancer
Christine B Weldon, Julia R Trosman, William J Gradishar, et al.
Journal of Cancer Research and Clinical Oncology
|
August 12, 2020
Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning
Yu Li, Aydin Eresen, Junjie Shangguan, et al.
World Journal of Gastroenterology
|
October 4, 2017
Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis
Al B Benson, Michael S Broder, Beilei Cai, et al.
Journal of Comparative Effectiveness Research
|
November 19, 2013
What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/Neu testing in breast cancer
Julia R Trosman, Christine B Weldon, Julian C Schink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 28, 2004
MAX2--a convenient index to estimate the average per patient risk for chemotherapy toxicity; validation in ECOG trials
M Extermann, M Bonetti, G W Sledge, et al.
Journal of Medical Economics
|
June 1, 2017
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR
Lynn Huynh, Todor Totev, Francis Vekeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
Weijing Sun, Mark Powell, Peter J O'Dwyer, et al.
Page
of 35